ARTICLE | Product Development
An arresting development
G1 aims to be first to market with a bone marrow chemoprotectant
September 29, 2014 7:00 AM UTC
G1 Therapeutics Inc.'s G1T28-1 cyclin dependent kinase 4 (CDK4) and CDK6 inhibitor could become the first compound in its class of cancer drugs to be marketed as a chemoprotectant. G1 is enrolling healthy subjects in a Phase I trial to assess safety, pharmacokinetics and pharmacodynamics.
Cancer researchers Ned Sharpless and Kwok-Kin Wong started the company in September 2012 with $600,000 in seed funding from Hatteras Venture Partners to develop therapies based on their discovery that inhibiting CDK4 and CDK6 arrests hematopoietic stem and progenitor cells in the G1 phase of the cell cycle, protecting them from chemotherapy and radiation damage...